This study assesses comparative resource use for patients given a new diagnosis of nonvalvular atrial fibrillation treated with dabigatran or warfarin in a real-world setting.
Matthew Sussman, MA
Advertisement
Articles by Matthew Sussman, MA
An incidence-based model was developed to estimate the annual ischemic and hemorrhagic stroke–related healthcare costs to a hypothetical US health plan with 1 million enrollees.
Advertisement
Latest Updated Articles
- Annual Stroke Costs to Health Plans Among Atrial Fibrillation Patients
Published: June 17th 2015 | Updated:
- Resource Use Among Nonvalvular Atrial Fibrillation Patients
Published: October 19th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
2
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer
3
FDA Approves Gazyva for Active Lupus Nephritis
4
Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings
5
